An acyltransferase AntB mutant and its application in the C8 acylation modification of the UK-2A backbone nucleus.

By mutating amino acid sites and enzymatic cascade reactions of the acyltransferase AntB, the problem of low acylation efficiency was solved, enabling diversified acylation modifications of the UK-2A skeleton core, thereby improving the bioactivity and antibacterial effect of the compound.

CN123107953APending Publication Date: 2026-11-17SHANGHAI JIAOTONG UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202611484184.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-22
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Acyltransferase AntB has low efficiency in catalyzing the acylation reaction at the C8 position of the UK-2A skeleton core, which is difficult to meet the requirements of synthesis. Existing technologies have not been able to effectively solve the problems of diversity and bioactivity optimization of the C8 position acylation modification of the core core.

Method used

By mutating specific amino acid sites of the acyltransferase AntB, mutants such as S17A, M265L, M384L, S17A-M265L, S17A-M384L, and S17A-M265L-M384L were prepared. These mutants were then combined with acyl-CoA ligase to carry out an enzyme cascade reaction, achieving diversified acylation modifications of the UK-2A backbone nucleus.

Benefits of technology

It improves catalytic efficiency, enhances the physicochemical properties and antifungal activity of compounds, breaks through the limitations of single acylation, provides a diverse library of acylated compounds, and significantly improves antibacterial activity against Candida albicans.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107953A_ABST
    Figure CN123107953A_ABST
Patent Text Reader

Abstract

This invention provides an acyltransferase AntB mutant and its application in the synthesis of UK-2A backbone C8 acylation modification. The mutant is a derived protein that retains acyltransferase activity, formed by substituting, deleting, or adding one or more amino acids to the acyltransferase AntB with the amino acid sequence shown in SEQ ID NO.1. This invention uses AntB protein and its mutant as acyltransferases in the process of converting UK-2-A acyl groups to UK-2-X. Compared with existing technologies, this method, by using the acyltransferase AntB mutant in the synthesis of UK-2-X, allows for the inhibition of the UK-2A backbone's unique Qi site activity while simultaneously introducing acyl side chains with different structures at the C8 position of the backbone. This enables the synthesis of UK-2A backbone compound derivatives with better physicochemical properties, bioavailability, and antifungal activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biological protease technology, specifically relating to an acyltransferase AntB mutant and its application in the synthesis of UK-2A backbone core C8 acylation modification. Background Technology

[0002] Fungal infections pose a serious threat to human health and agricultural production safety. Developing highly effective and safe new antifungal drugs has become a major public issue that urgently needs to be addressed in the fields of medicine, ecology, and agriculture.

[0003] Currently, the traditional antifungal drugs widely used in clinical practice mainly include azole drugs (such as ketoconazole, itraconazole, and fluconazole). These drugs exert their antifungal effect by inhibiting the synthesis of ergosterol in the fungal cell membrane. However, due to the high homology between fungi and most plants and mammals in drug target genes and protein sequences, traditional antifungal drugs generally suffer from insufficient target selectivity and host toxicity risks. More seriously, with the long-term and widespread use of antifungal drugs, a large number of drug-resistant strains have emerged in clinical practice and in the field, significantly reducing the control efficacy of existing drugs.

[0004] Polyketide natural products generally possess excellent pharmacological activities, demonstrating significant application potential in the pharmaceutical and agricultural fields. Antimycin and UK-2A, as two structurally highly related nine-membered ring dilactone polyketide-nonribosomal peptide hybrid natural products, both exhibit significant antifungal, antitumor, and mitochondrial respiratory chain inhibitory activities. Studies have shown that the parent skeleton of these two types of compounds is linked to specific aromatic acid units via amide bonds, and the structural diversity of their C8 acyl side chains has a decisive influence on the compounds' biological activity and cytotoxicity ratio. Therefore, acylation modification at the C8 position of the parent skeleton is a key approach to expanding the structural diversity of these compounds and optimizing their drug-like properties.

[0005] In the strategy for obtaining C8-position modified derivatives, the semi-synthetic route combining microbial fermentation and in vitro enzymatic transformation has shown advantages. Acyltransferase AntB, a key enzyme in the antifungal biosynthesis pathway, can specifically recognize the hydroxyl group at the C8 position of the parent nucleus and catalyze the transfer of different types of acyl donors to this site to form an ester bond. Using natural AntB enzymes for in vitro enzymatic reactions, diverse substitutions of the C8-position side chain of the antifungal backbone have been successfully achieved, providing a rich compound library for structure-activity relationship studies. Therefore, the development of novel antifungal drugs with new mechanisms of action, high selectivity, and low risk of cross-resistance has become a pressing public need in the fields of medicine, ecology, and agriculture.

[0006] Besides UK-2A, its natural homologues UK-2B, UK-2C, and UK-2D have also been isolated and identified, all possessing similar antifungal activity in their parent nuclei. However, the acylation modifications at the C8 position of the parent nucleus in these natural homologues are relatively simple, and existing techniques (such as "Unravelling the Biosynthetic Flexibility of UK-2A Enables Enzymatic Synthesis of Its Structural Variants" and "Multi-Targeting Non-Specific Genome Engineering in Bacteria") have not systematically studied specific site-specific acylation derivatization modifications of its structure, and the effects of different acyl substitutions on biological activity and drug performance are also lacking in-depth research. In further modification and development, how to precisely modify the structure of the parent nucleus at specific sites, and the influence of different acyl substitutions on the final biological activity and drug performance, have become key factors restricting the further expansion and optimization of this type of compound.

[0007] For example, CN104418833A discloses an antimycin analogue, its preparation method, and its uses, which has a structure as shown in Formula I: Formula I.

[0008] Chinese patent CN104418833A discloses an antimycin analogue and its preparation method. This method involves constructing a *Streptomyces* mutant strain AL2110 with a frame-locked deletion of the acyltransferase gene *antB* in the antimycin biosynthetic gene cluster, allowing the strain to accumulate deacylated antimycin intermediates. Based on this, various deacylated intermediates modified at R1 or R3 sites are obtained by adding carboxylic acid precursors (such as cinnamic acid, cyclohexylpropionic acid, and 6-fluorotryptophan) during the fermentation of the mutant strain. Further, the isolated deacylated intermediates are subjected to an in vitro enzymatic reaction with various coenzyme A derivatives catalyzed by the acyltransferase *antB*, introducing different acyl side chains at the C8 position of the parent nucleus to obtain a series of antimycin analogues. Experimental data show that some of the obtained antimycin analogues exhibit approximately 1 times higher antifungal activity and more than 66 times higher cytotoxicity than the natural antimycin A3b, confirming that regulating the R1 and R2 side chains can effectively control the antifungal activity and cytotoxicity of antimycin.

[0009] The inventors discovered that the acyltransferase AntB can catalyze the C8 acylation reaction of UK-2 using it as an acyl acceptor, thereby synthesizing a C8-acylated UK-2A skeleton core compound. This is a new application of AntB. However, the acyltransferase AntB has low catalytic efficiency for this reaction, and its Kc...cat / K m Only about 2.3mM -1 s -1 This makes it difficult to meet the requirements for preparing compounds with C8 acylation modification on the UK-2A skeleton core. Summary of the Invention

[0010] The purpose of this invention is to address the problem of low catalytic efficiency of acyltransferase AntB in C8 acylation reactions using UK-2 as a substrate. This invention provides an acyltransferase AntB mutant and its application in the synthesis of UK-2A backbone C8 acylation modifications. This solution provides an acyltransferase AntB mutant and its application, which can introduce acyl side chains with different structures at the C8 position of the UK-2A backbone, thereby enabling the synthesis of UK-2A backbone compound derivatives with better physicochemical properties, bioavailability, and antifungal activity.

[0011] The objective of this invention is achieved through the following technical solution: The first aspect of this invention discloses a mutant of the acyltransferase AntB, said mutant comprising one of the following proteins: Single mutants S17A, M265L, and M384L; double mutants S17A-M265L, S17A-M384L, M265L-M384L; and triple mutant S17A-M265L-M384L; in, The mutant S17A is obtained by changing the serine (S) at position 17 of the acyltransferase AntB to alanine (A); The mutant M265L is obtained by changing the methionine (M) at position 265 of the acyltransferase AntB to leucine (L). The mutant M384L is obtained by changing the methionine (M) at position 384 of the acyltransferase AntB to leucine (L). The double mutant S17A-M265L is obtained by changing the methionine (M) at position 265 of the mutant S17A to leucine (L); The double mutant S17A-M384L is obtained by changing the methionine (M) at position 384 of the mutant S17A to leucine (L). The double mutant M265L-M384L is obtained by changing the methionine (M) at position 384 of the mutant M265L to leucine (L); The triple mutant S17A-M265L-M384L is obtained by changing the methionine (M) at position 384 of the double mutant S17A-M265L to leucine (L). The amino acid sequence of the acyltransferase AntB mutant S17A is the amino acid sequence shown in SEQ ID NO.2; the amino acid sequence of the mutant M265L is the amino acid sequence shown in SEQ ID NO.3; the amino acid sequence of the mutant M384L is the amino acid sequence shown in SEQ ID NO.4; the amino acid sequence of the mutant S17A-M265L is the amino acid sequence shown in SEQ ID NO.5; the amino acid sequence of the mutant S17A-M384L is the amino acid sequence shown in SEQ ID NO.6; the amino acid sequence of the mutant M265L-M384L is the amino acid sequence shown in SEQ ID NO.7; and the amino acid sequence of the mutant S17A-M265L-M384L is the amino acid sequence shown in SEQ ID NO.8.

[0012] The second aspect of this invention discloses the application of an acyltransferase AntB mutant in the synthesis of UK-2A skeleton core C8 acylation modification, wherein the acyltransferase AntB and the acyltransferase AntB mutant are used in the preparation method of compounds obtained by UK-2A skeleton core C8 acylation modification; The compound UK-2-X has the following structure: UK-2-X; In the formula, the substituent R is selected from one of the substituents in Formulas 1 to 43: .

[0013] Furthermore, the preparation method includes the following steps: Under the co-catalysis of acyltransferase AntB or an acyltransferase AntB mutant and acyl-CoA ligase, compound UK-2, as a reaction precursor, undergoes an enzyme cascade reaction with a carboxylic acid substrate to obtain compound UK-2-X; The structure of the compound UK-2 is as follows: UK-2; Furthermore, the enzyme cascade reaction includes the following steps: Compound UK-2 was added to HEPES buffer, followed by the sequential addition of acyltransferase, acyl-CoA ligase, carboxylic acid substrate, ATP, soluble magnesium salt, and HS-CoA to induce an enzyme cascade reaction. The reaction product was extracted and separated, the organic solvent was removed, and the product was resuspended, centrifuged, and filtered to obtain the compound with the structure shown in UK-2-X.

[0014] Furthermore, the carboxylic acid substrate has a substituent R; The carboxylic acid substrate has the following structure: ; The substituent R is selected from, but is not limited to, one of the substituents in Formulas 1 to 43 below: Equations 1 to 43.

[0015] Furthermore, the acyl-CoA ligase includes the acyl-CoA ligase UKAQ. FAV and its mutants and acyl-CoA ligase AliA 100 ; Among them, the mutant and acyl-CoA ligase AliA 100 The amino acid sequence is the one shown in SEQ ID NO.9; Acyl-CoA ligase UKAQ FAV The amino acid sequence is the one shown in SEQ ID NO.10; Furthermore, the acyltransferase is preferably a double mutant S17A-M265L.

[0016] Furthermore, the enzyme cascade reaction involves HS-CoA, ATP, and Mg. 2+ It is carried out under the condition that it exists.

[0017] Furthermore, the reaction temperature of the enzyme cascade reaction is 15~25 °C, and the reaction time is 0.5~1 h.

[0018] Furthermore, the compound UK-2-X specifically has any one of the structures shown in UK-2-2, UK-2-3, and UK-2-38: UK-2-2; UK-2-3; UK-2-38.

[0019] The third aspect of this invention discloses the application of a compound based on the C8-position acylation modification of the UK-2A skeleton core in the preparation of a drug for inhibiting microbial growth or killing microorganisms.

[0020] Furthermore, the application of the compound based on the UK-2A skeleton core C8 acylation modification in the preparation of drugs that inhibit microbial growth or kill microorganisms includes: the drug comprising a compound having the structure shown in UK-2-X or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient; The microorganism mentioned is Candida albicans.

[0021] Compared with the prior art, the present invention has the following beneficial effects: 1) Overcoming the low catalytic efficiency of acyltransferase AntB in the C8 acylation modification of the UK-2A backbone. Acyltransferase AntB has a novel application in catalyzing the C8 acylation of UK-2 as a substrate, but its K... cat / K m Only about 2.3mM - 1 s -1 The S17A-M265L mutant provided by this invention increases this value to 10.1 mM. -1 s -1 (Approximately 4.45 times that of acyltransferase AntB), which improves the catalytic efficiency for acylation at the C8 position of the UK-2A nucleus, thereby solving the technical problem that the existing technology requires a large amount of enzyme or a long reaction time, making it difficult to meet the needs of preparing UK-2A type C8 acylated analogs.

[0022] 2) Balancing structural accessibility and core activity. The unique Qi site activity inhibition of the UK-2A skeleton is maintained even after C8 acylation modification. By introducing acyl side chains with different structures at the C8 position of the core, UK-2A skeleton derivatives with better physicochemical properties, bioavailability, and antifungal activity can be synthesized. Among them, UK-2-2, UK-2-3, and UK-2-38 have better antibacterial effects than UK-2A: In the antibacterial activity test against Candida albicans, the MIC values ​​of UK-2-2, UK-2-3, and UK-2-38 were 10.03 ng / mL, 15.05 ng / mL, and 3.76 ng / mL, respectively, which were significantly better than the control compound UK-2A's 40.13 ng / mL.

[0023] 3) The C8 position has changed from a single orientation to a diverse range of orientations. The diversity of R groups has been greatly improved. R can cover saturated or α / β unsaturated alkanes with 2-10 carbon atoms, as well as substituted acyl groups such as sulfur-containing alkyl and alkynyl groups; a single process can cover 43 structures from UK-2-1 to UK-2-43 in one go, breaking through the limitation of a single dominant acyl group at the C8 position of natural products.

[0024] 4) One-pot cascade preparation, efficient, time-saving, and simple to operate. In HEPES buffer, 3 µM acyltransferase S17A-M265L and ligase UKAQ are used. FAV / AliA 100 With synergistic catalysis, the enzyme cascade reaction can be completed in 1 h at 20 °C; all the target compounds mentioned above can be obtained by using UK-2 as a precursor. Attached Figure Description

[0025] Figure 1 Quantitative standard curve for HSCoA.

[0026] Figure 2 The diagram shows the kinetic parameters of AntB and its single mutant S17A on compound SPN-J.

[0027] Figure 3 The diagram shows the kinetic parameters of compound SPN-J for the single mutants AntB M265L and M384.

[0028] Figure 4 The diagram shows the kinetic parameters of compound SPN-J for the AntB double mutants S17A-M265L and S17A-M384.

[0029] Figure 5 The diagram shows the kinetic parameters of compound SPN-J for the AntB double mutant M265L-M384 and triple mutant S17A-M265L-M384.

[0030] Figure 6 Streptomyces in Example 1 Streptomyces huiliensis A schematic diagram of the a) ukaB gene knockout strategy of SCA2-4 and a UPLC characterization map of the fermentation products of the mutant strain (b)

[0031] Figure 7 This is the UK-2A standard curve.

[0032] Figure 8 For compound UK-2 1 H-NMR spectrum.

[0033] Figure 9 For compound UK-2 13 C-NMR spectrum.

[0034] Figure 10 This is the DEPT spectrum of compound UK-2.

[0035] Figure 11 The image shows the HMBC spectrum of compound UK-2.

[0036] Figure 12 The image shows the HSQC spectrum of compound UK-2.

[0037] Figure 13 This is the COSY spectrum of compound UK-2.

[0038] Figure 14 For compound UK-2A 1 H-NMR spectrum.

[0039] Figure 15 For compound UK-2A 13 C-NMR spectrum.

[0040] Figure 16 This is the DEPT spectrum of compound UK-2A.

[0041] Figure 17 The image shows the HMBC spectrum of compound UK-2A.

[0042] Figure 18 This is the HSQC spectrum of compound UK-2A.

[0043] Figure 19 This is the COSY spectrum of compound UK-2A.

[0044] Figure 20 The UPLC characterization spectra of UK-2-X (UK-2-1~UK-2-31) in Example 2 are shown.

[0045] Figure 21 The UPLC characterization spectra of UK-2-X (UK-2-31~UK-2-43) in Example 2 are shown.

[0046] Figure 22 HRMS diagrams for UK-2, UK-2A, UK-2B, UK-2C, UK-2D and UK2-2-1 to UK-2-3 in Example 3.

[0047] Figure 23 The HRMS diagrams for UK2-2-4 to UK-2-11 in Example 2 are shown.

[0048] Figure 24 The HRMS diagrams for UK2-2-12 to UK-2-19 in Example 2 are shown.

[0049] Figure 25The HRMS diagrams for UK2-2-20 to UK-2-27 in Example 2 are shown.

[0050] Figure 26 The HRMS diagrams for UK2-2-28 to UK-2-35 in Example 2 are shown.

[0051] Figure 27 The HRMS diagrams for UK2-2-36 to UK-2-43 in Example 2 are shown.

[0052] Figure 28 The results of the inhibition zone experiment of UK-2, UK-2A, blank group, control group and UK-2-X (UK-2-1~UK-2-43, excluding UK-2-19, UK-2-36 and UK-2-42) against Candida albicans in performance testing (1) are as follows.

[0053] Figure 29 For compound UK-2-38 1 H-NMR spectrum.

[0054] Figure 30 For compound UK-2-38 13 C-NMR spectrum.

[0055] Figure 31 This is the DEPT-NMR spectrum of compound UK-2-38.

[0056] Figure 32 The image shows the HMBC-NMR spectrum of compound UK-2-38.

[0057] Figure 33 The image shows the HSQC-NMR spectrum of compound UK-2-38.

[0058] Figure 34 The COSY-NMR spectrum of compound UK-2-38 is shown. Detailed Implementation

[0059] The present invention will now be described in detail with reference to the accompanying drawings and specific embodiments, but this does not limit the invention to the scope of the described embodiments. Experimental methods in the following embodiments that do not specify specific conditions are performed according to conventional methods and conditions, or as selected according to the product instructions. The technical solutions of the present invention will be further described in detail below with reference to specific embodiments. It should be understood that the following embodiments are merely illustrative and explanatory of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are covered within the scope of protection intended by the present invention.

[0060] In this invention, the preparation method of the UK-2A homologue is conventional in the art, generally obtained through biosynthesis, i.e., fermentation using Streptomyces, the same fungus used to produce UK-2A. Preferably, Streptomyces is used. Streptomyces huiliensis SCA2-4 is the chassis; Streptomyces Streptomyces huiliensis SCA2-4 was derived from *Streptomycesuiliensis* sp. nov. and deposited at the China Center for Type Culture Collection (CCTCC) on March 30, 2021, with accession number CCTCCNO:M 2021298. Based on this, CRISPR-Cas9-mediated genome editing technology (Efficient Editing DNA Regions with High Sequence Identity in Actinomycetal Genomes by a CRISPR-Cas9 System) was further employed. Synthetic and Systems Biotechnology 4, (2019): 86-91.), knocking out the ukaB gene (SEQ ID NO.11) to obtain a mutant strain. Streptomyces huiliensis SCA2-4:ΔukaB. This mutant strain can specifically accumulate the deacylation precursor UK-2, providing a substrate source for downstream acylation reactions.

[0061] In this invention, the preparation method of the compound with the structure shown in UK-2-X is conventional in the art, generally involving reacting compound UK-2 with an acyl donor under the action of an acyltransferase. The acyltransferase can be conventional in the art, as long as it can attach the acyl donor to the C8 hydroxyl group of compound UK-2, and is not particularly limited. In specific embodiments of this invention, the acyltransferase is preferably a mutant of acyltransferase AntB, S17A-M265L; the acyl donor is the acyl-CoA synthase UKAQ triple mutant UKAQ disclosed in patent CN114717208B. FAV or acyl-CoA ligase AliA 100 The substrate carboxylic acid (purchased from Anaiji Pharmaceutical Chemicals Co., Ltd., structural formula shown in Table 1) was reacted with HS-CoA to obtain AliA. 100 From the article Use of the Rhodopseudomonas palustrisgenomesequence to identify a single amino acid that contributes to the activity of a coenzyme A ligase with chlorinated substrates. Molecular Microbiology, 2005, 55: 1151-1159.

[0062] Table 1. Structural formulas of 43 carboxylic acid substrates and corresponding acyl-CoA synthases The carboxylic acid substrate does not need to be specifically limited; the same carboxylic acid precursor can be selected based on the R group in compounds such as UK-2-X.

[0063] Unless otherwise specified, all materials and reagents used in the following examples are commercially available: Candida albicans Candida albicans ATCC10231.

[0064] The acyltransferase used in the following examples is the biological mutant S17A-M265L of the acyltransferase AntB disclosed in CN104418833A. The preparation method of this acyltransferase mutant S17A-M265L is as follows: Step 1) Constructing a heterologous expression plasmid for the acyltransferase AntB mutant S17A-M265L: The antB gene fragment was synthesized and ligated into pet28a to obtain a recombinant plasmid. The recombinant plasmid was transformed into E. coli DH5α, and single colonies were picked for amplification and culture. After amplification, sequencing verification was performed, and the correct plasmid was labeled p-antB. Using p-antB as a template, amplification was performed using primers S17F-F (as shown in SEQ ID NO.12: TATGTGGCCCAGCGCGCCCGCGCCTTTCTGAGTT) and S17F-R (as shown in SEQ ID NO.13: TCAGAAAGGCGCGGGCGCGCTGGGCCACATAC). The amplified system was digested with DpnI enzyme at 37℃ for 3 h and then transformed into... E. coliSingle colonies of DH5α were selected and amplified. After amplification, sequencing was performed to verify that the correct plasmid was S17A. Using S17A as a template, primers M265L-F (as shown in SEQ ID NO.14: TGTGCTGGGTTGTCTCAGTCCGGTTGATCTGCGT) and M265L-R (as shown in SEQ ID NO.15: CAGATCAACCGGACTGAGACAACCCAGCACACGC) were used for amplification. The amplified system was digested with DpnI enzyme at 37℃ for 3 h and then transformed into E. coli DH5α. Single colonies were selected and amplified. After amplification, sequencing was performed to verify that the correct plasmid was S17A-M265L. S17A-M265L was transformed into E. coli BL21(DE3).

[0065] Step 2) Heterologous expression and purification of acyltransferase S17A-M265L: The strain p-S17A-M265L carrying the heterologous expression plasmid of S17A-M265L was inoculated into LB medium (10 g / L tryptone, 5 g / L yeast extract, 10 g / L NaCl) and cultured at 37°C and 220 rpm on a shaker until OD600 = 0.6. IPTG was added to a final concentration of 100 mM. After expression at 18°C ​​for 20 hours, the cells were collected by centrifugation at 4000 rpm and 4°C. The cells were resuspended in lysis buffer (20 mM Hepes, 300 mM NaCl, 10% glycerol, pH 7.5), sonicated at 4°C, and centrifuged at 10000 rpm and 4°C. The supernatant was separated using a nickel column to obtain S17A-M265L. The obtained S17A-M265L protein was concentrated by ultrafiltration using a 30kD ultrafiltration tube, and then stored at -80℃ for later use.

[0066] UkaQ and AliA 100 The protein preparation method is the same as described above.

[0067] This invention discloses a compound (a homologue of UK-2A) based on different acylation modifications of the UK-2A skeleton (C8 position of the parent nucleus). While maintaining the Qi site inhibitory activity unique to the UK-2A skeleton, the invention aims to improve the physicochemical properties, bioavailability, and antifungal activity of the compound by introducing acyl side chains with different structures. This provides a lead compound basis for the development of novel antibacterial drugs with independent intellectual property rights, high activity, and low risk of drug resistance.

[0068] The structural formula of compound UK-2-X is shown below: UK-2-X; In UK-2-X, R is selected from saturated or α / β-unsaturated alkanes with a total number of carbon atoms of 2 to 10, or acyl side chains containing substituents. Preferably, the substituents are selected from at least one of thioalkyl, alkynyl, cycloalkyl, aryl, chlorine, bromine, mercapto, thiophene, carboxyl, cyano, and trifluoromethyl groups.

[0069] In a specific embodiment of the present invention, R in UK-2-X is selected from the following groups: .

[0070] The present invention further discloses a method for preparing the above-mentioned compound: using the compound shown in UK-2 as a precursor, under the co-catalysis of acyltransferase and acyl-CoA ligase, UK-2 is reacted with a carboxylic acid substrate and HS-CoA, ATP, and Mg. 2+ An enzyme cascade reaction (one-pot enzymatic acylation) was performed to prepare the compound shown in the diagram for UK-2-X. The reaction process is illustrated in the following equation: The structure of the compound shown in UK-2 is as follows: UK-2.

[0071] The present invention further discloses the application of the above-mentioned compounds, specifically a pharmaceutical composition comprising a compound as shown in UK-2-X or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

[0072] In this invention, the pharmaceutical composition can be a pharmaceutical composition conventionally understood in the art, used to treat diseases, such as as a topical antifungal agent; or used to treat pests and diseases, such as as an antifungal agent for fruits and vegetables. The main function of this pharmaceutical composition is to inhibit or kill microbial growth. Specifically, for example, it is used in fisheries production to specifically eliminate harmful fish. Those skilled in the art will understand that microorganisms generally refer to prokaryotic and / or eukaryotic microorganisms, such as bacteria and / or fungi. In a specific embodiment of this invention, the microorganism is Candida albicans, for example, Candida albicans. Candida albicans ATCC10231.

[0073] Example 1 Preparation of compound UK-2.

[0074] 1) The ukaB gene in Streptomyces huiliensis SCA2-4 ( S. huiliensis Missing boxes in SCA2-4 The sgRNA obtained by annealing two oligonucleotides, ukaB-sgRNA-F and ukaB-sgRNA-R, was cloned into the EcoRI / XbaI restriction site of the pMWCas9 plasmid to obtain the recombinant plasmid pMWCas9-sgB. Two homologous arm fragments, each 2.1 kb in length, were obtained using primer pairs ukaB-Larm-F / R and ukaB-Rarm-F / R. These two homologous arms were further cloned into the HindIII / SpeI restriction site of pMWCas9-sgB to construct the recombinant plasmid pMWCas9-ΔB.

[0075] ukaB-sgRNA-F (SEQ ID NO.16):AATTCGCGTCGCCCTGTCCGCCGACGTTTTAGAG; ukaB-sgRNA-R (SEQ ID NO. 17): CTAGCTCTAAAACGTCGGCGGACAGGGCGACGCG; ukaB-Larm-F (SEQ ID NO.18):GGAGGCCGTGCTCGGCGTCGAC; ukaB-Larm-F (SEQ ID NO.19):GTGCAGTCCTCAAGTGGGCAGAG; ukaB-Rarm-F (SEQ ID NO. 20):CTCTGCCCACTTGAGGAGCTGCACGAGCGGATCGCGGACGCCGG; ukaB-Rarm-R (SEQ ID NO. 21):TCGAGCGTGGCCCACCCCCAGT; pMWCas9-ΔB was introduced into a UK-2A-producing Streptomyces strain. S. huiliensisIn SCA2-4, an indirect co-transfer method between Escherichia coli and Streptomyces was used. Escherichia coli containing pMWCas9-ΔB was mixed with Streptomyces strain S. huiliensis SCA2-4 at a 1:1 volume ratio and spread onto MS medium (formulation: 100 mL containing 2 g soybean meal, 2 g D-mannitol, and 2 g agar powder). After incubation at 30°C for 12 h, 1 mL of sterile water containing 50 μg / mL apramycin and 50 μg / mL nalidixic acid was evenly spread on the plate. After drying in a sterile environment, the plate was incubated at 30°C for 2-3 days until apramycin-resistant transformants appeared. Alpramycin-resistant transformants were first inoculated into TSB liquid medium containing 2 mg / L thiotetracycline (TSB 30 g / L, agar 20 g / L) and cultured at 30°C for 24 hours to induce CRISPR-Cas9-mediated cleavage; then transferred to MS agar medium. Five rounds of subculturing were performed in MS medium under apramycin-free conditions. Genotyping of the obtained apramycin-sensitive strains was performed, and recombinant strains with inactivated ukaB genes were finally screened. S. huiliensis SCA2-4:ΔukaB, as shown Figure 6 As shown. The construction of the pMWCas9 plasmid and the specific principles and operations of this process are described in the following reference: Efficient Editing DNA Regions with High Sequence Identity in Actinomycetal Genomes by a CRISPR-Cas9 System, Synthetic and Systems Biotechnology 4, (2019): 86-91.

[0076] (2) Fermentation production of UK-2 and UK-2A Recombinant Streptomyces strains S. huiliensis SCA2-4:ΔukaB was inoculated into TSB medium (TSB 30 g / L, agar 20 g / L) and cultured on a shaker at 28℃ and 220 r / min for 2 days. Then, it was transferred to ISP2 fermentation medium (malt extract 10 g / L, glucose 10 g / L, yeast extract 4 g / L) at a ratio of 10% and fermented on a shaker at 28℃ and 220 r / min for 48 h. After that, an equal volume of ethyl acetate was added to extract the fermentation broth, and after rotary evaporation and concentration, compound UK-2 was obtained by HPLC semi-preparation.

[0077] Recombinant Streptomyces strains S. huiliensisSCA2-4 was inoculated into TSB medium (TSB 30 g / L, agar 20 g / L) and cultured on a shaker at 28℃ and 220 r / min for 2 days. Then, it was transferred to ISP2 fermentation medium (malt extract 10 g / L, glucose 10 g / L, yeast extract 4 g / L) at a ratio of 10% and fermented on a shaker at 28℃ and 220 r / min for 48 h. After that, an equal volume of ethyl acetate was added to extract the fermentation broth, and after rotary evaporation and concentration, compound UK-2A was obtained by HPLC semi-preparation.

[0078] The prepared UK-2 and UK-2A were subjected to NMR analysis using a Bruno 600 M NMR spectrometer and deuterated DMSO as the solvent. The results are as follows. Figure 7-19 As shown, in Figure 8 For compound UK-2 1 H-NMR spectrum, Figure 9 For compound UK-2 13 C-NMR spectrum, Figure 10 The DEPT spectrum of compound UK-2 is shown. Figure 11 The HMBC spectrum of compound UK-2 is shown. Figure 12 The HSQC spectrum of compound UK-2 is shown. Figure 13 This is the COSY spectrum of compound UK-2.

[0079] Figure 14 For compound UK-2A 1 H-NMR spectrum, Figure 15 For compound UK-2A 13 C-NMR spectrum, Figure 16 The DEPT spectrum of compound UK-2A is shown. Figure 17 The HMBC spectrum of compound UK-2A is shown. Figure 18 The HSQC spectrum of compound UK-2A is shown. Figure 19 This is the COSY spectrum of compound UK-2A.

[0080] As can be seen from the above test results, the compounds shown in UK-2A and UK-2 were obtained in Example 1.

[0081] Example 2 Construction, protein expression, and activity assay of AntB mutants (1) Construction of heterologous expression plasmids for acyltransferase AntB mutants: The AntB gene fragment was synthesized and ligated into pet28a to obtain recombinant plasmids. The recombinant plasmids were transformed into E. coli DH5α, single colonies were picked and amplified, and the amplified colonies were sequenced for verification. The correct plasmid was labeled as p-antB. Using p-antB as a template, the following primers were used: S17A-F (as shown in SEQ ID NO.22: TATGTGGCCCAGCGCGCCCGCGCCTTTCTGAGT), S17A-R (as shown in SEQ ID NO.23: TCAGAAAGGCGCGGGCGCGCTGGGCCACATAC), M265L-F (as shown in SEQ ID NO.24: TGTGCTGGGTTGTCTCAGTCCGGTTGATCTGCGT), M265L-R (as shown in SEQ ID NO.25: CAGATCAACCGGACTGAGACAACCCAGCACACGC), M384L-F (as shown in SEQ ID NO.26: GGTCGTAGCCCGGTTCTGGCCTGCGTGGTTAGT), and M384L-R (as shown in SEQ ID NO.26: GGTCGTAGCCCGGTTCTGGCCTGCGTGGTTAGT). As shown in NO.27, the plasmids ACTAACCACGCAGGCCAGAACCGGGCTACGACC were amplified separately. After amplification, the system was digested with DpnI enzyme at 37℃ for 3 hours and then transformed into E. coli DH5α. Single colonies were picked and amplified and cultured. After amplification, sequencing was performed to verify that the correct plasmids were labeled as S17A, M265L, and M384L, respectively. Using S17A as a template, amplification was performed using primers M265L-F (as shown in SEQ ID NO.28: TGTGCTGGGTTGTCTCAGTCCGGTTGATCTGCGT) and M265L-R (as shown in SEQ ID NO.29: CAGATCAACCGGACTGAGACAACCCAGCACACGC). The amplified system was digested with DpnI enzyme at 37℃ for 3 h and then transformed into E. coli DH5α. Single colonies were picked and amplified, and the amplification was verified by sequencing. The correct plasmid was labeled as S17A-M265L, and S17A-M265L was transformed into E. coli BL21(DE3).Using S17A as a template, amplification was performed using primers M384L-F (as shown in SEQ ID NO.30: GGTCGTAGCCCGGTTCTGGCCTGCGTGGTTAGT) and M384L-R (as shown in SEQ ID NO.31: ACTAACCACGCAGGCCAGAACCGGGCTACGACC). The amplified system was digested with DpnI enzyme at 37℃ for 3 h and then transformed into E. coli DH5α. Single colonies were picked and amplified, and the amplification was verified by sequencing. The correct plasmid was labeled as S17A-M384L. S17A-M384L was then transformed into E. coli BL21(DE3). Using M265L as a template, amplification was performed using primers M384L-F (as shown in SEQ ID NO.32: GGTCGTAGCCCGGTTCTGGCCTGCGTGGTTAGT) and M384L-R (as shown in SEQ ID NO.33: ACTAACCACGCAGGCCAGAACCGGGCTACGACC). The amplified system was digested with DpnI enzyme at 37℃ for 3 h and then transformed into E. coli DH5α. Single colonies were picked and amplified, and the amplification was verified by sequencing. The correct plasmid was labeled as M265L-M384L. M265-M384L was then transformed into E. coli BL21(DE3). Using S17A-M265L as a template, amplification was performed using primers M384L-F (as shown in SEQ ID NO.34: GGTCGTAGCCCGGTTCTGGCCTGCGTGGTTAGT) and M384L-R (as shown in SEQ ID NO.35: ACTAACCACGCAGGCCAGAACCGGGCTACGACC). The amplified system was digested with DpnI enzyme at 37℃ for 3 h and then transformed into E. coli DH5α. Single colonies were picked and amplified, and the amplification was verified by sequencing. The correct plasmid label was S17A-M265L-M384L. S17A-M265-M384L was transformed into E. coli BL21(DE3).

[0082] (2) Heterologous expression and purification of acyltransferase AntB and its mutants S17A, S17A-M265L, S17A-M384L, M265L-M384L and S17A-M265L-M384L: Strains carrying heterologous expression plasmids of AntB, S17A, S17A-M265L, S17A-M384L, M265L-M384L and S17A-M265L-M384L were inoculated into LB (tryptone 10 g / L, yeast extract 5 g / L, NaCl 10 g / L) and cultured at 37℃ and 220 rpm in a shaker until OD600=0.6. IPTG was added to a final concentration of 100 mM. After expression at 18℃ for 20 hours, the cells were collected by centrifugation at 4000 rpm and 4℃. The bacterial cells were resuspended in lysis buffer (20 mM Epes, 300 mM NaCl, 10% glycerol, pH 7.5), sonicated at 4°C, and centrifuged at 10,000 rpm at 4°C. The supernatant was separated into proteins AntB, S17A, S17A-M265L, S17A-M384L, M265L-M384L, and S17A-M265L-M384L using a nickel column. The obtained AntB, S17A, S17A-M265L, S17A-M384L, M265L-M384L, and S17A-M265L-M384L proteins were ultrafiltered, desalted, concentrated, and stored at -80°C for later use.

[0083] UkaQ FAV and AliA 100 The method for protein preparation is the same as described above.

[0084] (3) Establishment of HS-CoA quantitative standard curve: The HS-CoA quantitative standard curve was established using the DTNB method. The HS-CoA standard stock solution was accurately prepared and serially diluted with 50 mM HEPES buffer (pH 7.5) to obtain a series of standard solutions with concentrations of 0, 20, 40, 60, 80, 100 and 150 µM.

[0085] Take 100 µL of each of the above-mentioned standard solutions and mix it with 100 µL of DTNB working solution (final concentration 1 mM, prepared with 50 mM HEPES buffer). Incubate at room temperature in the dark for 20 min to allow the free thiol groups to react completely with DTNB, generating the yellow product TNB (2-nitro-5-thiobenzoic acid). Use an equal volume of HEPES buffer instead of HSCoA standard solution as a blank control and treat it in the same way.

[0086] After the reaction was completed, the absorbance of each reaction solution was measured at 412 nm. The net absorbance (ΔA) was calculated by subtracting the absorbance of the blank control from the absorbance of each concentration of standard solution.412 A linear regression was performed with the molar concentration of HSCoA (µM) as the x-axis and the y-axis as the ordinate. The results are as follows: Figure 1 The equation of the standard curve shown is as follows: ; (R 2 =0.9991).

[0087] Where y is the net absorbance value after subtracting the blank, and x is the HSCoA concentration (µM). The results show that the HSCoA concentration and the net absorbance value have a good linear relationship in the concentration range of 0–150 µM.

[0088] (4) Reaction kinetics determination of AntB and its mutants: Using hexanoyl-CoA as the acyl donor and compound SPN-J as the acyl acceptor, the initial reaction rate was determined by continuously monitoring the increase of absorbance at 412 nm using the DTNB reagent colorimetric method (the free thiol group in product HSCoA reacts with DTNB to generate the yellow product TNB).

[0089] The reaction system (300 µL) contained: 50 mM HEPES buffer (pH 7.5), 1 mM hexanoyl-CoA, 0.1 mM MDTNB, and gradient concentrations of compound SPN-J (final concentrations of 10, 25, 50, 100, 250, 500, and 1000 µM). After equilibration at 30°C for 5 minutes, approximately 1 µM of purified enzyme was added to initiate the reaction. The absorbance changes during the initial stage of the reaction (e.g., the first 2 minutes) were continuously monitored at 412 nm using a spectrophotometer, and the linear slope of the absorbance increase over time was recorded.

[0090] Plotting the concentration of SPN-J on the x-axis (x) and the initial reaction rate (V0, µM / min) on the y-axis, the kinetic parameter K was calculated using Origin 9.0 software based on the Michaelis-Menten equation for nonlinear fitting. m and V max All experiments were performed in triplicate, and data are presented as mean ± standard deviation (SD).

[0091] The structural formula of compound SPN-J is as follows: SPN-J.

[0092] The results are as follows Figure 2-5 As shown, where, Figure 2 The kinetic parameters of AntB and its single mutant S17A on compound SPN-J are shown in the figure. Figure 3The kinetic parameters of compound SPN-J are plotted for AntB single mutant M265L and single mutant M384. Figure 4 The kinetic parameters of compound SPN-J are shown in the diagrams of the AntB double mutants S17A-M265L and S17A-M384. Figure 5 The diagram shows the kinetic parameters of compound SPN-J for the AntB double mutant M265L-M384 and triple mutant S17A-M265L-M384.

[0093] The results showed that among these variants, S17A-M265L exhibited the highest catalytic activity, superior to all single mutants, with its K0... cat / K m The value is 10.1 mM -1 s -1 It is 4.45 times that of the acyltransferase AntB.

[0094] Example 3 Enzymatic preparation of UK-2-X compound: The UK-2 obtained in Example 1 was further acylated in a 1.5 mL EP tube, with a total volume of 100 µL. 3 µM of the acyltransferase S17A-M265L and 3 µM of the acyl-COA ligase UKaQ were added to 50 mM HEPES buffer (pH 7.5). FAV (Used for the synthesis of UK-2-1~UK-2-25 and UK-2-29~UK-2-42) or AliA 100 (Used for the synthesis of UK-2-26~UK-2-28 and UK-2-43), 0.4 mM carboxylic acid substrate with 0.3 mM UK-2, 0.5 mM ATP, and 2 mM Mg 2+ 0.4 mMHS-CoA was added. The reaction was carried out at 20℃ for 1 h. The product was extracted with 2 volumes of ethyl acetate, and after removing the organic solvent, the product was resuspended in 50 µL of chromatographic grade methanol. The mixture was centrifuged at high speed and filtered through a 0.22 µm filter membrane. The concentration of the acylated product was quantified according to the quantitative curve of standard UK-2A. The quantitative curve of standard UK-2A is shown below. Figure 7 As shown, the regression equation is: ; Where x is the concentration of UK-2A (0-0.6mM) and y is the absorption peak area at 254nm.

[0095] According to the preparation method of this embodiment, compounds with different acylation modifications based on the UK-2A skeleton, as shown in UK-2-1 to UK-2-43, were obtained.

[0096] UPLC results of the compounds shown in UK-2-1 to UK-2-43 are as follows: Figure 20 and Figure 21 As shown, the instrument used was a Shimadzu ultra-high performance liquid chromatograph equipped with a PDA detector. HRMS detection of the compounds shown in UK-2-1 to UK-2-43 is as follows: Figure 22-27 As shown, where, Figure 22 The HRMS plots are for UK-2, UK-2A, UK-2B, UK-2C, UK-2D, and UK2-2-1 to UK-2-3 in Example 3. Figure 23 The HRMS diagrams for UK2-2-4 to UK-2-11 in Example 2 are shown below. Figure 24 The HRMS diagrams for UK2-2-12 to UK-2-19 in Example 2 are shown below. Figure 25 The HRMS diagrams for UK2-2-20 to UK-2-27 in Example 2 are shown below. Figure 26 The HRMS charts for UK2-2-28 to UK-2-35 in Example 2 are shown below. Figure 27 The HRMS diagrams for UK2-2-36 to UK-2-43 in Example 2 are shown.

[0097] The mass spectrometer used for the analysis was a Thermo Fisher Orbitrap 120, employing positive ion mode. The ion source was ESI, with the electrospray voltage set to 3500 V, the ion transfer tube temperature set to 325℃, and the evaporation temperature set to 350℃. Figure 21-26 It can be seen that the compounds shown in UK-2-1 to UK-2-43 were prepared using the preparation method of Example 2. The series spectra of UK-2-38 are shown below. Figures 29-34 As shown, where, Figure 29 For compound UK-2-38 1 H-NMR spectrum, Figure 30 For compound UK-2-38 13 C-NMR spectrum, Figure 31 The DEPT-NMR spectrum of compound UK-2-38 is shown below. Figure 32 The HMBC-NMR spectrum of compound UK-2-38 is shown below. Figure 33 The HSQC-NMR spectrum of compound UK-2-38 is shown below. Figure 34 The COSY-NMR spectrum of compound UK-2-38 is shown.

[0098] Based on implementation cases 1-3, compounds UK-2-1 to UK-2-43 were obtained, providing a compound library for screening novel small molecule antibacterial drugs.

[0099] Performance testing: (1) Inhibition zone test This performance test is for the antifungal activity of compound UK-2-X: Will Candida albicans Overnight culture of ATCC10231 was mixed at a ratio of 2% into thawed and slightly cooled Sabouraud medley medium, and then plated. 5 µL of the compounds (50 µM concentration) shown in the above-prepared UK-2-1 to UK-2-43 (except UK-2-19 and UK-2-36) were dropped onto a 6 mm diameter filter paper disc. After the solvent evaporated, the filter paper disc was flatly placed onto a fungal plate and incubated overnight at 30°C for 12 h. An inhibition zone was observed. Figure 28 Positive control: UK-2A; negative control: methanol (MeOH); blank control: Control.

[0100] Figure 28 It is evident that UK-2-2, UK-2-3, and UK-2-38 exhibit superior antibacterial effects.

[0101] (2) MIC test This performance test assesses the antifungal activity of compounds UK-2-2, UK-2-3, and UK-2-38. a. Preparation of bacterial suspension Will Candida albicans ATCC 10231 was streaked onto Sabouraud dextrose agar plates and incubated upside down at 37°C for 24 h. Single colonies were picked, mixed with ddH2O, and the OD was measured at 530 nm using a spectrophotometer. 530 Using sterile ddH2O as a blank control, adjust the concentration to 0.08-0.13, which is 0.5 McFarland turbidity, and then dilute it 10 times and 100 times for later use.

[0102] b. Gradient formulation of compounds The methanol solutions of the preferred compounds preliminarily screened from the inhibition zone experiment, containing UK-2-2, UK-2-3, and UK-2-38 respectively, were added to the first column of a 96-well plate. After evaporation, 100 µL of 2×RPMI-1640 medium (containing 2% DMSO, pH 5.2) was added. 100 µL was taken from the first column and serially diluted 2-fold to the tenth column. After mixing the tenth column, the 100 µL was discarded to obtain the gradient concentration drug culture medium solutions.

[0103] c. Inoculation and Culture Add 100 µL of bacterial culture to the first 11 columns (final concentration approximately 0.5~2.5×10⁻⁶). 3(CFU / mL), column 12 shows 100 µL of ddH2O added as a blank control. Simultaneously, bacterial culture plating verification was performed: a 10-fold diluted bacterial culture was further diluted 2-fold, 10 µL was added to 2 mL of ddH2O, mixed well, and 100 µL was plated onto a Sabouraud dextrose agar plate. After 12 h of incubation, colony counts were performed (the colony count should be 5–125 corresponding to the initial bacterial concentration). The 96-well plates were sealed and incubated at 30°C for 12 h, and OD was measured using a microplate reader. 530 Calculate the inhibition rate (if the positive control OD) 530 If the value is less than 0.2, extend the culture time by 12-24 h. Calculate the inhibition rate using the following formula: ; Wherein: ODNC is the negative control well OD 530 Reading; ODS is the OD of the sample well. 530 Reading; ODBC is the blank control well OD 530 reading.

[0104] d. Positive controls and results 5-Fluorocytosine (5-FC) was used as a positive control (10 mg / mL stock solution, diluted 100 times with ddH2O). The first row of each plate was the 5-FC control, and serial dilutions were performed using the same method.

[0105] The results showed that, using the absence of visible growth (i.e., 100% inhibition) as the MIC criterion, the MIC values ​​of UK-2-2, UK-2-3, and UK-2-38 were 10.03, 15.05, and 3.76 ng / mL, respectively, all superior to the control compound UK-2A (40.13 ng / mL). This indicates that the C8 structural modification of the UK-2A skeleton not only preserves the core activity but also further broadens its antibacterial activity.

[0106] The above description of the embodiments is provided to enable those skilled in the art to understand and use the invention. It will be apparent to those skilled in the art that various modifications can be made to these embodiments, and the general principles described herein can be applied to other embodiments without inventive effort. Therefore, the present invention is not limited to the above embodiments, and any improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the invention should be within the protection scope of the present invention.

Claims

1. A mutant of the acyltransferase AntB, characterized in that, The mutant includes one of the following proteins: Single mutants S17A, M265L, and M384L; double mutants S17A-M265L, S17A-M384L, M265L-M384L; and triple mutant S17A-M265L-M384L; in, The single mutant S17A is obtained by changing the serine (S) at position 17 of the acyltransferase AntB to alanine (A) mutant. The single mutant M265L is obtained by changing the methionine (M) at position 265 of the acyltransferase AntB to leucine (L). The single mutant M384L is obtained by changing the methionine (M) at position 384 of the acyltransferase AntB to leucine (L). The double mutant S17A-M265L is obtained by changing the methionine (M) at position 265 of the mutant S17A to leucine (L); The double mutant S17A-M384L is obtained by changing the methionine (M) at position 384 of the mutant S17A to leucine (L). The double mutant M265L-M384L is obtained by changing the methionine (M) at position 384 of the mutant M265L to leucine (L); The triple mutant S17A-M265L-M384L is obtained by changing the methionine (M) at position 384 of the double mutant S17A-M265L to leucine (L). The amino acid sequence of the acyltransferase AntB mutant S17A is the amino acid sequence shown in SEQ ID NO.2; the amino acid sequence of the mutant M265L is the amino acid sequence shown in SEQ ID NO.3; the amino acid sequence of the mutant M384L is the amino acid sequence shown in SEQ ID NO.4; the amino acid sequence of the mutant S17A-M265L is the amino acid sequence shown in SEQ ID NO.5; the amino acid sequence of the mutant S17A-M384L is the amino acid sequence shown in SEQ ID NO.6; the amino acid sequence of the mutant M265L-M384L is the amino acid sequence shown in SEQ ID NO.7; and the amino acid sequence of the mutant S17A-M265L-M384L is the amino acid sequence shown in SEQ ID NO.

8.

2. The application of the AntB mutant acyltransferase or AntB acyltransferase as described in claim 1 in the synthesis of the UK-2A backbone core C8 acylation modification, characterized in that, The acyltransferase AntB mutant or acyltransferase AntB is used to prepare the compound UK-2-X obtained by acylation modification at the C8 position of the UK-2A backbone nucleus; The compound UK-2-X has the following structure: UK-2-X; In the formula, the substituent R is selected from one of the substituents in Formulas 1 to 43: 。 3. The application of the acyltransferase AntB mutant according to claim 2 in the acylation modification at the C8 position of the UK-2A backbone nucleus, characterized in that, The preparation method includes the following steps: Under the co-catalysis of acyltransferase AntB or an acyltransferase AntB mutant and acyl-CoA ligase, compound UK-2, as a precursor, undergoes an enzyme cascade reaction with a carboxylic acid substrate to yield compound UK-2-X; wherein, the structure of compound UK-2 is as follows: UK-2.

4. The application of the acyltransferase AntB mutant according to claim 3 in the synthesis of UK-2A backbone C8 acylation modification, characterized in that, The carboxylic acid substrate has a substituent R; The carboxylic acid substrate has the following structure: ; The substituent R is selected from one of the substituents in Formulas 1 to 43: 。 5. The application of the acyltransferase AntB mutant according to claim 3 in the acylation modification of the C8 position of the UK-2A backbone nucleus, characterized in that, The acyltransferase used is a double mutant S17A-M265L.

6. The application of the acyltransferase AntB mutant according to claim 3 in the acylation modification of the C8 position of the UK-2A backbone nucleus, characterized in that, The acyl-CoA ligase includes the acyl-CoA ligase UKAQ. FAV Acyl-CoA ligase AliA 100 ; Among them, acyl-CoA ligase AliA 100 The amino acid sequence is the one shown in SEQ ID NO.9; The mutant UKaQ of acyl-CoA ligase UKaQ FAV The sequence is the amino acid sequence shown in SEQ ID NO.

10.

7. The application of the acyltransferase AntB mutant according to claim 3 in the acylation modification of the C8 position of the UK-2A backbone nucleus, characterized in that, The enzyme cascade reaction described involves HS-CoA, ATP, and Mg. 2+ It is carried out under the condition that it exists.

8. The application of the acyltransferase AntB mutant according to claim 3 in the acylation modification of the C8 position of the UK-2A backbone nucleus, characterized in that, The enzyme cascade reaction is carried out at a temperature of 15-25 °C for 0.5-1 h.

9. The application of the acyltransferase AntB mutant according to claim 3 in the acylation modification of the C8 position of the UK-2A backbone nucleus, characterized in that, The compound UK-2-X specifically has any of the structures shown in UK-2-2, UK-2-3, and UK-2-38: UK-2-2; UK-2-3; UK-2-38.

10. The application of a compound based on the C8-position acylation modification of the UK-2A skeleton core in the preparation of drugs that inhibit microbial growth or kill microorganisms.

Citation Information

Patent Citations

  • Antitoxin analogue as well as preparation method and application thereof

    CN104418833A